<DOC>
	<DOCNO>NCT02379676</DOCNO>
	<brief_summary>The purpose study compare effect ticagrelor clopidogrel endothelial dysfunction vascular inflammation Ticagrelor lead beneficial pleiotropic effect compare treatment clopidogrel patient receive drug-eluting stent ( DES ) percutaneous coronary intervention ( PCI ) non-ST-segment acute coronary syndrome ( NSTE-ACS ) beyond 1 month index event . Ticagrelor treatment improve percent flow-mediated dilation ( FMD ) value reduce inflammatory gene expression peripheral blood mononuclear cell .</brief_summary>
	<brief_title>Effect Ticagrelor Versus Clopidogrel Endothelial Dysfunction Vascular Inflammation</brief_title>
	<detailed_description>The primary objective study lie whether ticagrelor improve endothelial dysfunction compare clopidogrel , measure endothelium-dependent flow-mediated dilation ( FMD ) . The secondary objective demonstrate whether ticagrelor anti-atherosclerotic effect compare clopidogrel term reduce systemic low-grade inflammation . Endpoints 1 ) difference flow-mediated dilation value , 2 ) messenger ribonucleic acid ( mRNA ) expression measure quantitative real-time reverse transcription-polymerase chain reaction ( qRT-PCR ) inflammation-associated key gene circulation monocytes non-ST-segment acute coronary syndrome patient treat ticagrelor clopidogrel . Patients agree participate study screen Visit 1 ( 30 ~ 365 day index percutaneous coronary intervention ) . Patients endothelial dysfunction define screen flow-mediated dilation randomly assign Visit 2 ( 0~7 day screen test ) . And , patient receive study drug accord allocated group day randomization . Ticagrelor 90mg twice daily clopidogrel 75mg daily maintain 30 day . Flow-mediated dilation perform screen Visit 3 ( day 30 treatment study drug ) blood sample perform first dose study drug Visit 2 Visit 3 .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Men woman ≥20 year age Documented history nonSTsegment acute coronary syndrome occur 30 ~ 365 day prior randomization successfully treat percutaneous coronary intervention use drugeluting stent Patient currently prescribe tolerate aspirin 100mg clopidogrel 75mg . Patient demonstrate endothelial dysfunction define percent flowmediated dilation value low 7 % baselines test Patients angina relate symptom Patients undergo failed invasive treatment Patients history hypersensitivity ticagrelor clopidogrel Patients take anticoagulant , antithrombotic regularly study , plan continuous treatment study Patients take vasoactive agent caffeine ingestion &lt; 48 Patients decompensated congestive heart failure cardiogenic shock ( Killip classification III IV ) Patients intractable arrhythmia Patients intractable arrhythmia Patients second third degree atrioventricular block Patients uncontrolled hypertension Patients high risk hemorrhage like blood coagulation disorder , gastrointestinal bleeding , gross hematuria , intraocular bleeding , hemorrhagic stroke , intracranial hemorrhage Patients moderate chronic obstructive pulmonary disease diagnose symptom document pulmonary function test Patients require renal replacement therapy Patients moderate severe hepatic impairment Patients platelet &lt; 100,000/μL Patients hematocrit &lt; 30 % Concomitant oral parenteral therapy strong cytochrome P450 3A4 inhibitor , cytochrome P450 3A substrate narrow therapeutic index , strong cytochrome P450 3A4 inducer ) Strong inhibitor : ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin ( erythromycin azithromycin ) , nefazadone , ritonavir , saquinavir , nelfinavir , indinavir , atanazavir , 1 litre daily grapefruit juice ii ) Substrates narrow therapeutic index : cyclosporine , quinidine , simvastatin dos &gt; 40 mg daily lovastatin dose &gt; 40 mg daily iii ) Strong inducer : rifampin/rifampicin , rifabutin , phenytoin , carbamazepine , phenobarbital Patient need take drug study medication allow concomitant medication study period . Patients plan elective surgery invasive procedure require temporary discontinue study medication study period . Patients pregnant , breast feeding use medically acceptable birth control . Patients consider unsuitable base medical judgment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>